BMS-684

• Description:

  BMS-684 is a selective DGKα inhibitor with an IC50 of 15 nM. BMS-684 inhibits DGKα kinase activity with >100-fold selectivity over the related DGK type I family members DGKβ and DGKγ. BMS-684 does not inhibit any of the other seven DGK isozymes[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H315, H319, H335

• Target:

  DGK

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/bms-684.html

• Purity:

  99.76

• Solubility:

  DMSO : 14.29 mg/mL (ultrasonic; warming)

• Smiles:

  CN (C1=CC=CC=C1C (N2CCN (C (C3=CC=CC=C3) C4=CC=CC=C4) CC2) =C5[N+] ([O-]) =O) C5=O

• Molecular Formula:

  C27H26N4O3

• Molecular Weight:

  454.52

• Precautions:

  H315, H319, H335

• References & Citations:

  [1]Michael Wichroski, et al. DGKα/ζ inhibitors combine with PD-1 checkpoint therapy to promote T cell-mediated antitumor immunity. Sci Transl Med. 2023 Oct 25;15 (719) :eadh1892.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  313552-29-3